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LETTERS TO THE EDITOR 
Asymptomatic Cardiac Ischemia Pilot 
(ACIP) Study 
I read with great interest the recently published results of the 
Asymptomatic Cardiac Ischemia Pilot (ACIP) study (1-3), and al- 
though I support most of the conclusions drawn, I do not agree with all. 
Additionally, I find that important information that might help us to 
understand the partly surprising and disappointing results has not been 
reported. Therefore, I have a number of questions that I hope the 
ACIP Investigators will find time to answer. 
Comments. In the 1-year follow-up study, one of the conclusions 
stated by the ACIP Investigators is that the revascularization strategy 
"appeared to be far superior to either angina-guided or ischemia- 
guided strategy in suppressing both ambulatory ECG and exercise test 
evidence of ischemia" (2). This is certainly true regarding ambulatory 
ischemia, but when applied to the results of exercise testing, this 
conclusion isnot correct. From the data presented in Table 3 (2) it is 
evident hat the proportion of patients with ->l-mm ST segment 
depression on exercise testing at the 1-year visit was similar in the three 
treatment strategies: 70% in the angina-guided, 76% in the ischemia- 
guided and 71% in the revascularization strategy. From Table 3 (2) it 
is also obvious that the severity of myocardial ischemia s judged from 
the size of maximal ST segment depression and the exercise time to 
1-mm ST segment depression were similar in the three treatment 
strategies. However, the proportion of patients with exercise-induced 
angina at 1-year follow-up was significantly reduced in "surgically" 
treated patients: 27% in the angina-guided strategy, 36% in the 
ischemia-guided strategy and 20% in revascularization strategy. In my 
opinion, therefore, the ACIP data suggest that revascularization 
results in an immediate significant reduction in exercise-induced 
angina compared with the results of medical therapy (1,2). At the 
1-year visit, the symptomatic benefit of revascularization still exceeded 
the symptomatic benefit of medical treatment (2). Revascularization 
was also superior to medical therapy in the early suppression of 
exertional ST segment depression (1,2). During follow-up the effect of 
revascularization  exercise-induced ST segment depression was 
practically unchanged, whereas the beneficial effect of medical therapy 
appeared to improve. As a result, the prevalence and severity of 
exercise-induced ST segment depression i  revascularized and medi- 
cally treated patients were practically identical at 1-year follow-up (2). 
Questions. One of the prerequisites for inclusion in the ACIP study 
was ECG evidence of myocardial ischemia on exercise testing. Isch- 
emia was defined as l) J point and ST segment level 80 ms after the J 
point (ST80) depression ->1.0 mm, ST segment horizontal or 
downsloping <1 mV/s; or 2) ST 80 depression ->1.5 mm and ST 
segment upsloping >1 mV/s (4). Although I am aware that ST segment 
depression of type 2 may represent myocardial ischemia (5), most 
investigators in this field exclusively use the type 1 definition. In the 
ACIP study the proportion of patients with exertional ST segment 
depression was surprisingly high in all three treatment s rategies atany 
time after intervention: 66% to 88% (2). From a theoretical point of 
view, these findings might be accounted for in part by the inclusion of 
upsloping ST segment depression as a general marker of myocardial 
ischemia. Itwould be interesting to know how large a proportion of the 
study population that had ST segment depression oftype 1 respectively 
type 2 at the qualifying visit and during follow-up? In other words, does 
intervention influence the two types of ST segment depression in 
different ways? 
It is well recognized that intervention and bypass surgery in 
particular may cause alterations in the rest ECG. The development of
new repolarization changes will make interpretation fthe ST segment 
more difficult in some cases. In the ACIP study the proportion of 
normal rest ECG results in the three treatment strategies was similar 
at the qualifying visit (Table 2 [1]). At 12-week follow-up, after 
intervention, the proportion of normal rest ECG responses in medi- 
cally treated patients (angina plus ischemia guided) had increased to 
-59%, whereas the proportion of normal rest ECG responses in the 
revascularized group was reduced to 40% (p < 0.001) (1). Can these 
intervention-induced changes on the rest ECG (partly) explain the 
significantly different occurrences ofST segment depression on ambu- 
latory monitoring and exercise testing in medically treated versus 
patients with revascularization at the 12-week visit? (1). 
In the coronary angioplasty versus bypass study, no data are 
reported regarding the proportion of normal rest ECG results in the 
coronary angioplasty respectively bypass surgery subgroups (3). It 
might be expected that more patients in the bypass urgery group 
would have rest ECG abnormalities after intervention than those 
undergoing coronary angioplasty (6). If so, these rest ECG changes 
might also influence the prevalence of ambulatory and exercise- 
induced ST segment depression at the subsequent 12-week visit. Is it 
possible for the ACIP Investigators (3) to inform us regarding the rest 
ECG data in the coronary angioplasty and bypass urgery subgroups 
before and after intervention? 
Has there so far been any final decision as to the initiation of the 
previously planned National Heart, Lung, and Blood Institute-funded 
large-scale (>5,000 patients), long-term mortality study? 
I would like to finish with some general information for the readers 
of the Journal. Studies assessing the long-term prognosis (>4 years) of 
ambulatory ischemia re now available (7-9). The applicability of the 
results is limited by small study populations, but despite this reserva- 
tion I find it interesting that in none of the reports that address patients 
with stable angina (7), previous bypass urgery (8) or recent myocardial 
infarction (9), was the presence of ambulatory ST segment depression 
of any help in identifying subgroups at increased risk of cardiac death 
or myocardial infarction during an extended period of follow-up. 
These data, of course, will need confirmation by larger scale trials. 
HANS MICKLEY, MD, DRMEDSC, 
Department of Cardiology 
Odense University Hospital 
5000 Odense C, Denmark 
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Asymptomatic Cardiac Ischemia Pilot (ACIP) 
Study: What Clinical Implications Does 
It Have? 
Occasionally readers do not delve deeply into scientific articles and 
sometimes just read the conclusions or the discussion sections. We 
think that in two recently published articles from the ACIP Investiga- 
tors (1,2) the authors printed irrelevant conclusions and suggested 
misleading clinical implications. 
In 1994 the ACIP study design and baseline data (3) and 12-week 
results (4) were reported. No significant difference was found between 
the ischemia-guided medical approach and the revascularization strat- 
egy regarding ambulatory electrocardiographic (ECG) variables and 
total event numbers. Reported ata were also suggestive for a superior 
antiischemic effect of the atenolol plus nifedipine combination com- 
pared with the diltiazem plus isosorbide dinitrate regimen. Important 
remarks were made, and some major APIC study limitations were 
pointed out in an editorial by Deedwania (5). 
In their article, Rogers et al. (2) selectively interpret their data of 
the 12-month ACIP study exercise test results. They neglected to 
mention that by 12 months, except for the number of patients with 
exercise-induced angina, the difference for all other variables indicat- 
ing ischemia became insignificant between the three strategies. Also 
there is a clear trend indicating a continuous improvement on both 
medical arms and a slight worsening on the revascularization arm 
(Table 3 in their article). Regarding ACIP 12-weeks ambulatory ECG 
data, Knatterud et al. (4) correctly reported previously that they found 
ambulatory ischemia suppressed in 52% of patients assigned to 
atenolol and nifedipine in the ischemia-guided group, which does not 
seem to be significantly different from the 55% corresponding value in 
the revascularization group. Why do Rogers et al. fail to publish 
12-month data on the atenolol plus nifedipine subgroup instead of 
concluding that exercise ECG outcomes appear to be superior in the 
revascularization group? Rogers et al. found the number of deaths 
significantly higher only in the angina-guided group and found no 
significant difference between the two other groups. Furthermore, they 
report no deaths in the revascularization group (n -- 192!), and we also 
consider this unusual. Rogers et al. calculate that even with one death 
in the revascularization strategy the overall significance would be lost. 
Are not they misleading when stating in the section on clinical 
implications that "these pilot data also suggest that survival of patients 
with asymptomatic ischemia may be prolonged by revascularization" 
even if they continue with "but a larger scale trial with a longer follow 
up duration is needed for confirmation"? 
Chaitman et al. (1) report on ACIP 12-week exercise test outcomes 
and conclude that revascularization was significantly superior to either 
medical strategy in reducing exercise-induced ischemia. In the same 
volume of the Journal, Rogers et al. (2) reported 12-month exercise 
outcomes that showed none of the significant differences reported by 
Chaitman et al. Chaitman et al. also report that "at the 12-week visit, 
the percent of patients without an ischemic episode or event (death, 
myocardial infarction, nonprotocol coronary revascularization proce- 
dure, exercise-induced myocardial ischemia) was 18.2%, 19.4% and 
33.7% in the angina-guided, ischemia-guided and revascularization 
strategies, respectively (p < 0.001)." We do not understand bow these 
figures were calculated and cannot find where they come from even 
after reviewing other reports on ACIP data (2-4). Furthermore we 
cannot agree with any combination of "hard" events and exercise- 
induced ischemia. 
All authors hould very cautiously interpret their data because they 
may unintentionally exert a significant impact on medical decision 
making. In this aspect he responsibility of investigators working for 
larger multicenter studies is certainly greater because these studies 
attract considerable attention even in the pilot phase. 
Gfid3OR ANDRASSY, MD 
GYULA KERKOVITS, MD, PHD 
Department of Cardiology 
Saint Francis Hospital 
71-73 Szdher f~t 1021 Budapest, Hunga~ 
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Reply 
We appreciate the interest in our reports by Andrassy et al. and 
Mickley. 
The primary purpose of the Asymptomatic Cardiac lschemia Pilot 
Study (ACIP), like all pilot studies, was to determine the feasibility of 
a larger scale, more definitive trial. We agree and fully acknowledged 
in our publication (1) that clinical outcomes in the pilot study should 
be interpreted with caution because the sample size (although the 
largest ever reported in a controlled trial of medical therapy vs. 
revascularization for asymptomatic cardiac ischemia) is small, the 
duration of follow-up is short, and the number of clinical events is few. 
Nevertheless, we cannot ignore the trends that emerged in the pilot 
study favoring revascularization. These trends were directionally con- 
sistent not only with regard to clinical outcomes, uch as death or death 
plus myocardial infarction, but also with ischemia findings on serial 
ambulatory electrocardiography and treadmill exercise testing. 
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At 12 months patients assigned to revascularization were not only 
less likely to experience angina on exercise testing, but exercised to a 
higher rate-pressure product and achieved a higher percent of age 
predicted maximal heart rate before experiencing angina. We find no 
indication that exercise performance in the revascularization group 
"worsened" over i-year follow-up. The percentage of patients with 
exercise-induced angina at the 12-week, &month and 12-month visits 
was 25%, 20% and 20%, respectively, and the percentage with >-1 mm 
ST segment depression was 69%, 66% and 71%, respectively. We 
agree that exercise-induced ischemia lessened in the medical arms 
during 1-year follow-up. However, this finding is due largely to 
performance of coronary revascularization in the medical group (i.e., 
crossovers) rather than to improvement of exercise-induced ischemia 
over time with continued medical therapy alone. Exercise-induced 
ischemia was seen in 85% (of those crossovers) versus 70% (continued 
on medical therapy alone) in the angina-guided strategy at the 12-week 
versus the 12-month visit and in 88% versus 76% in the ischemia- 
guided strategy. The reduction in exercise-induced ischemia t 12 
months in those assigned to medical therapy is related in part to 
performance of revascularization procedures. In patients assigned to 
angina-guided therapy, exercise-induced ischemia occurred at the 
1-year visit in 42% of patients who underwent revascularization (i.e., 
crossovers) compared with 77% of patients continuing on medical 
therapy when no revascularization procedure was added (p = 0.004). 
Similarly, in the group assigned to ischemia-guided therapy, exercise- 
induced ischemia occurred in 58% of patients who underwent revas- 
cularization (i.e., crossovers) compared with 82% of patients who 
continued on medical therapy alone (p = 0.01). 
The purpose of the 1-year outcome report was to present 
intermediate-term follow-up data from the three randomly assigned 
treatment s rategies. The detailed results of the subgroup comparisons 
of medical treatment with the combination of atenolol plus nifedipine 
versus diltiazem plus isosorbide dinitrate will be published shortly (2). 
Andrassy et al. also raised the question that the frequency of 
exercise-induced ischemia should be analyzed alone and not combined 
with "hard" events. In a randomized, controlled trial analyzed accord- 
ing to the intention to treat principle, it is necessary toaccount for all 
patients. It would be misleading to present exercise-induced ischemia 
only in any particular treatment strategy without also accounting for 
other ischemic heart disease adverse vents, uch as death, myocardial 
infarction or hospital admission for increasing angina, that may have 
precluded performance of the exercise test. Accordingly, the ACIP 
Investigators decided before the trial began that the primary outcome 
variable would be the result of the test for ischemia or an event if one 
occurred. The data published are the percentage of patients free of 
death, myocardial infarction, nonprotocol coronary revascularization 
procedure, hospital admission and exercise-induced myocardial isch- 
emia. 
In response to Mickley's comments, the percentage ofpatients with 
exertional ST segment depression is not accounted for by those with a 
slow upsloping ischemic ST segment response. In the ACIP study, 
there were only 4, 2, 0 and 0 patients at the qualifying visit, posttherapy 
12-week and 6- and 12-month visits, respectively, that met ECG 
evidence for ischemia based solely on the slow upsloping ST segment 
response. This is related to the fact that horizontal or downsloping ST 
segment depression was noted concomitantly in other monitored leads 
during the exercise test, as is often the case (3). It should he noted that 
ACIP entry criteria required all patients to have exercise-induced ST 
segment depression on the qualifying test and that life-table analysis, 
rather than crude percentages, were used. This method of analysis i  
the more appropriate analysis for censored ata (4). For example, at 
the 12-week visit, exercise-induced ST segment depression was noted 
in 58% of patients (101 of 173) assigned revascularization when crude 
rates were used compared with 69% when life-table stimates adjusted 
for censored ata were used. 
When the exercise ECG data were examined by presence or 
absence of abnormalities on the rest ECG at the 12-week visit, the 
percentage of patients in the angina-guided, ischemia-guided and 
revascularization strategies with exercise-induced ischemia was 91%, 
86% and 64% (p < 0.000l) when 12-week rest ECG results were 
abnormal and when the 12-week rest ECG was normal, the incidence 
was 82%, 89% and 77%, respectively (p = 0.85). Thus, in those 
assigned to the revascularization strategy, reduction of ischemia t 12 
weeks occurred primarily in patients who had an abnormal rest ECG. 
When patients assigned to revascularization were examined, ab- 
normal ECG results were more frequent in patients who underwent 
bypass grafting than angioplasty at 12 weeks, 80% versus 49% 
(p <0.001) and at 12 months 72% versus 40% (p <0.001). Neverthe- 
less, at 12 months exercise-induced ST segment depression was less 
frequent in patients who underwent bypass grafting than in patients 
who had angioplasty (54% vs. 82%, p = 0.006) (5). The p values 
comparing the two revascularization procedures can only be consid- 
ered suggestive evidence because they are not based on a comparison 
of the randomized groups. 
A final question raised by Mickley concerns the possible lack of 
association between ambulatory ECG ischemia nd longer term 
outcomes. If current hinking about he pathophysiology of biologically 
active coronary artery disease (e.g., ulcers, thrombus, endothelial 
dysfunction) and the link between this activity and ST segment shifts 
on ambulatory ECG monitoring is correct, some active lesions would 
be expected to heal over time. Other patients may have lesions that 
become active, so the marker provided by ambulatory ECG monitoring 
for predicting high risk for early or intermediate-term adverse out- 
come may not predict high risk in long-term follow-up (6). There are 
data to support his suggestion (7-9). 
Finally, we would like to underscore our position that the ACIP 
1-year outcome data, while favoring revascularization, are not defini- 
tive and should not be construed as an endorsement ofrevasculariza- 
tion as the optimal treatment for patients with asymptomatic is hemia. 
Rather, ACIP should be interpreted as a successful pilot study, 
showing the feasibility and need for a larger scale study with sufficient 
sample size to determine the effect of different ischemia treatments on 
clinical outcomes, uch as death and myocardial infarction. We remain 
committed to performing such a study if resources become available. 
There has not been a final decision rendered yet on the National 
Heart, Lung, and Blood Institute-funded ACIP II trial. 
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